Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 23, 2026, 10:27 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Diagnostic study only Clear all
Recruiting Phase 2 Interventional

A Study of Mosunetuzumab Alone or With Zanubrutinib in People With Follicular Lymphoma

NCT05389293
View directory record Official record
Conditions
Follicular Lymphoma, Lymphoma
Interventions
Mosunetuzumab, Zanubrutinib
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
152 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
9
States / cities
Washington D.C., District of Columbia • Basking Ridge, New Jersey • Hackensack, New Jersey + 6 more
Source: ClinicalTrials.gov public record
Updated Aug 9, 2026 · Synced Sep 23, 2026, 10:27 AM EDT
Completed Phase 1 Interventional Results available

Testing the Safety of Adding Either Monalizumab (IPH2201) or Oleclumab (MEDI9447) to Durvalumab (MEDI4736) Plus Standard Radiation Therapy for Locally Advanced Non-small Cell Lung Cancer (NSCLC), ARCHON-1 Trial

NCT03801902
View directory record Official record
Conditions
Locally Advanced Lung Non-Small Cell Carcinoma, Locally Recurrent Lung Non-Small Cell Carcinoma, Stage II Lung Cancer AJCC v8, Stage III Lung Cancer AJCC v8, Unresectable Lung Non-Small Cell Carcinoma
Interventions
Accelerated Hypofractionated Radiation Therapy, Biospecimen Collection, Computed Tomography, Durvalumab, Magnetic Resonance Imaging of the Brain with and without Contrast, Monalizumab, Oleclumab, Radiation Therapy
Radiation · Procedure · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
56
States / cities
Atlanta, Georgia • Augusta, Georgia • Boise, Idaho + 42 more
Source: ClinicalTrials.gov public record
Updated Sep 22, 2025 · Synced Sep 23, 2026, 10:27 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of Two Doses of 18F-AV-45 in Alzheimer's Disease and Healthy Volunteers

NCT01565330
View directory record Official record
Conditions
Alzheimer Disease
Interventions
florbetapir F 18
Drug
Lead sponsor
Avid Radiopharmaceuticals
Industry
Eligibility
35 Years and older
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
3
States / cities
West Palm Beach, Florida • North East, Maryland • Clementon, New Jersey
Source: ClinicalTrials.gov public record
Updated Jun 17, 2012 · Synced Sep 23, 2026, 10:27 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Peripheral Immune System in Individuals With Schizophrenia

NCT05109065
View directory record Official record
Conditions
Schizophrenia, Schizo Affective Disorder, Schizophreniform Disorders
Interventions
SCID (Standardized Clinical Interview for DSM-V), PSS (Perceived Stress Score), Urine Toxicology Screen, Vitals, Blood Work, PQ-B, COVID Screening, Positive and Negative Syndrome Scale (PANSS)
Diagnostic Test
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 40 Years
Enrollment
63 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2024
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Jun 5, 2025 · Synced Sep 23, 2026, 10:27 AM EDT
Terminated Phase 3 Interventional Results available

Safety and Efficacy Study of Trans Sodium Crocetinate (TSC) in Newly Diagnosed Glioblastoma (GBM) Biopsy-Only Subjects

NCT03393000
View directory record Official record
Conditions
Glioblastoma
Interventions
Trans Sodium Crocetinate plus SOC, Standard of Care (SOC)
Drug · Other
Lead sponsor
Diffusion Pharmaceuticals Inc
Industry
Eligibility
18 Years to 70 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
13
States / cities
Irvine, California • Redwood City, California • Santa Monica, California + 10 more
Source: ClinicalTrials.gov public record
Updated Jul 21, 2021 · Synced Sep 23, 2026, 10:27 AM EDT
Completed Phase 1 Interventional

Viral Therapy in Treating Patients With Relapsed or Refractory Multiple Myeloma

NCT01533194
View directory record Official record
Conditions
Light Chain Deposition Disease, Refractory Plasma Cell Myeloma
Interventions
Diagnostic Laboratory Biomarker Analysis, Wild-type Reovirus
Other · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 14, 2015 · Synced Sep 23, 2026, 10:27 AM EDT
Completed No phase listed Observational

Proximal Molecular Effects of Concurrent Chemoradiotherapy on Head and Neck Squamous Cell Carcinoma

NCT00620139
View directory record Official record
Conditions
Head and Neck Squamous Cell Carcinoma
Interventions
the arachidonic acid and EGFR signaling pathways and their interaction in HNSCC tumorigenesis,
Biological
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2013
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 23, 2013 · Synced Sep 23, 2026, 10:27 AM EDT
Completed No phase listed Observational

Mobilization and Outcomes After Venous Closure

NCT07246902
View directory record Official record
Conditions
Venous Vascular Closure, Electrophysiology Study
Interventions
MYNX CONTROLTM VENOUS Vascular Closure Device
Device
Lead sponsor
Cordis US Corp.
Industry
Eligibility
Not listed
Enrollment
339 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
9
States / cities
Los Angeles, California • Palo Alto, California • Littleton, Colorado + 6 more
Source: ClinicalTrials.gov public record
Updated Sep 17, 2026 · Synced Sep 23, 2026, 10:27 AM EDT
Recruiting Not applicable Interventional

Acupuncture and Chinese Herbal Medicine for Long COVID

NCT07285707
View directory record Official record
Conditions
Long COVID
Interventions
Acupuncture
Procedure
Lead sponsor
Southern California University of Health Sciences
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Whittier, California
Source: ClinicalTrials.gov public record
Updated Dec 15, 2025 · Synced Sep 23, 2026, 10:27 AM EDT
Terminated Phase 1 Interventional

A Study of Pre-Operative Treatment of Newly-Diagnosed, Surgically-Resectable Osteosarcoma With Doxorubicin, Ifosfamide, Etoposide, and Cisplatin With Early Metabolic Assessment of Response

NCT01258634
View directory record Official record
Conditions
Osteosarcoma, Lung Metastases
Interventions
Dexrazoxane, Doxorubicin, Cisplatin, G-CSF, PEG-filgrastim, Etoposide, Ifosfamide, Mesna, Leucovorin
Drug
Lead sponsor
University of Chicago
Other
Eligibility
2 Years to 35 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Dec 9, 2013 · Synced Sep 23, 2026, 10:27 AM EDT
Terminated Phase 1Phase 2 Interventional

JSP191 Antibody Targeting Conditioning in SCID Patients

NCT02963064
View directory record Official record
Conditions
SCID
Interventions
Humanized anti-CD117 Monoclonal Antibody (JSP191)
Biological
Lead sponsor
Jasper Therapeutics, Inc.
Industry
Eligibility
3 Months to 12 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2025
U.S. locations
9
States / cities
Los Angeles, California • Palo Alto, California • San Francisco, California + 6 more
Source: ClinicalTrials.gov public record
Updated Jul 27, 2025 · Synced Sep 23, 2026, 10:27 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Early Detection of Breast Cancer Using Tomosynthesis Imaging

NCT00637598
View directory record Official record
Conditions
Breast Neoplasms
Interventions
Mammography and tomosynthesis imaging
Radiation
Lead sponsor
Duke University
Other
Eligibility
Female only
Enrollment
385 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2013
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 12, 2017 · Synced Sep 23, 2026, 10:27 AM EDT
Active, not recruiting Phase 2 Interventional

Daratumumab, Carfilzomib, Lenalidomide and Low Dose Dexamethasone (DKRd) in Newly Diagnosed, Multiple Myeloma

NCT03500445
View directory record Official record
Conditions
Myeloma, Multiple Myeloma
Interventions
Daratumumab, Carfilzomib, Lenalidomide, Dexamethasone
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 12, 2026 · Synced Sep 23, 2026, 10:27 AM EDT
Recruiting Phase 2 Interventional

The CARDIOPROTECT Trial

NCT07654426
View directory record Official record
Conditions
Diffuse Large B-cell Lymphoma (DLBCL), Cardiotoxicity, Lymphoma
Interventions
Dexrazoxane, Dexrazoxane placebo, Doxorubicin, Liposomal Doxorubicin, Cyclophosphamide, Vincristine, Prednisone, Rituximab, Polatuzumab Vedotin
Drug
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2035
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 26, 2026 · Synced Sep 23, 2026, 10:27 AM EDT
Withdrawn Not applicable Interventional

Diagnostic Accuracy of Ferumoxytol-Enhanced MRI for Detecting Lymph Node Metastases in Colorectal Cancer

NCT01983371
View directory record Official record
Conditions
Colorectal Cancer
Interventions
Ferumoxytol, Magnetic Resonance Imaging
Drug · Other
Lead sponsor
Scott Potenta, MD, PhD
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Burlington, Vermont
Source: ClinicalTrials.gov public record
Updated May 19, 2016 · Synced Sep 23, 2026, 10:27 AM EDT
Recruiting No phase listed Observational

The Prevalence of Directional Preference in the Lumbar Stenosis Population

NCT07007663
View directory record Official record
Conditions
Lumbar Stenosis
Interventions
Not listed
Lead sponsor
NYU Langone Health
Other
Eligibility
48 Years and older
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Lake Success, New York
Source: ClinicalTrials.gov public record
Updated May 3, 2026 · Synced Sep 23, 2026, 10:27 AM EDT
Completed Phase 2 Interventional Results available

An Open Label Phase II Pharmacokinetic and Pharmacodynamic Assessment of the Potential for QTc Prolongation Following First Induction Treatment With CPX-351 (Cytarabine:Daunorubicin) Liposome Injection in Acute Leukemias and MDS Patients

NCT02238925
View directory record Official record
Conditions
Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL), Myelodysplastic Syndrome (MDS)
Interventions
CPX-351
Drug
Lead sponsor
Jazz Pharmaceuticals
Industry
Eligibility
18 Years to 80 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
5
States / cities
Indianapolis, Indiana • Westwood, Kansas • Portland, Oregon + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 29, 2017 · Synced Sep 23, 2026, 10:27 AM EDT
Completed Phase 2 Interventional Results available

Study to Establish Image Interpretation Criteria for 18F Fluciclovine PET in Detecting Recurrent Brain Metastases (PURSUE)

NCT04410367
View directory record Official record
Conditions
Brain Metastases
Interventions
18F fluciclovine
Drug
Lead sponsor
Blue Earth Diagnostics
Industry
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
9
States / cities
Santa Monica, California • New Haven, Connecticut • Miami, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Jul 19, 2025 · Synced Sep 23, 2026, 10:27 AM EDT
Terminated Phase 4 Interventional Results available

PREA, PK And Safety PASS Study Of IV Pantoprazole In Pediatric Subjects

NCT02401035
View directory record Official record
Conditions
Gastroesophageal Reflux Disease
Interventions
IV pantoprazole
Drug
Lead sponsor
Pfizer
Industry
Eligibility
1 Year to 16 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
3
States / cities
Dallas, Texas • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Apr 8, 2024 · Synced Sep 23, 2026, 10:27 AM EDT
Completed Phase 2 Interventional Results available

Cardiovascular Effects of COVID-19

NCT04365699
View directory record Official record
Conditions
COVID-19
Interventions
AT-001
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 15, 2021 · Synced Sep 23, 2026, 10:27 AM EDT
Completed No phase listed Observational Accepts healthy volunteers Results available

Fujifilm DBT Plus S-View Versus FFDM Alone in the Detection of Breast Cancer - A Pivotal Study

NCT03501693
View directory record Official record
Conditions
Breast Cancer
Interventions
DBT plus S-View, FFDM Alone
Device
Lead sponsor
Fujifilm Medical Systems USA, Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Norwalk, Connecticut
Source: ClinicalTrials.gov public record
Updated Sep 20, 2023 · Synced Sep 23, 2026, 10:27 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Study of New Catheter & Pressure Monitor System to Help Prevent Compartment Syndrome From Developing in the Injured Leg

NCT00681616
View directory record Official record
Conditions
Compartment Syndrome
Interventions
Compartment Monitoring System (CMS), Compartment Monitoring System with Active Fluid Removal, Compartment Monitoring System without fluid removal
Device
Lead sponsor
Twin Star Medical, Inc.
Industry
Eligibility
18 Years to 60 Years
Enrollment
90 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
13
States / cities
Orange, California • San Francisco, California • Denver, Colorado + 9 more
Source: ClinicalTrials.gov public record
Updated Mar 3, 2009 · Synced Sep 23, 2026, 10:27 AM EDT
Terminated Phase 1 Interventional Results available

A Study of Intratumoral/Intralesional Administration of V938 in Combination With Pembrolizumab (MK-3475) in Participants With Advanced/Metastatic or Recurrent Malignancies (V938-001)

NCT04135352
View directory record Official record
Conditions
Neoplasm Metastasis
Interventions
200 mg of pembrolizumab, V938
Drug · Biological
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
3
States / cities
San Francisco, California • Houston, Texas • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Nov 11, 2024 · Synced Sep 23, 2026, 10:27 AM EDT
Terminated Phase 2Phase 3 Interventional Results available

Study on Functional Electrical Stimulation (FES) Cycling Following Spinal Cord Injury

NCT01217047
View directory record Official record
Conditions
Spinal Cord Injury
Interventions
FES Cycling, Cycling without FES, Lumbar puncture, Mood assessment
Device · Procedure · Behavioral
Lead sponsor
Hugo W. Moser Research Institute at Kennedy Krieger, Inc.
Other
Eligibility
18 Years to 65 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 26, 2021 · Synced Sep 23, 2026, 10:27 AM EDT